《半新股》海普瑞(09989.HK)逆市急涨11%重越20天线 A股涨停
恒指反弹受制25,200,掉头失守10天及50天线,曾急吐461点或1.8%低见24,641喘定,现跌357点或1.4%报24,744;国指也吐1.1%曾低见10,093。
不过,半新医药股海普瑞(09989.HK)承昨天倒升结束三连跌後,今早逆市急涨重越10天及20天线(16.07元及16.8元),最高见17.8元,仍受制上市价18.4元,现造17.58元,急涨11%,成交急增至1,029万股,涉资1.77亿元;其A股涨停报27.9元人民币。
海普瑞是内地领先制药公司,在制药领域、创新生物科技领域及CDMO领域拥有全球业务。股份於7月8日以每股18.4元来港上市,但上市後股价仅三个交易日盘中曾企稳於上市价之上,最高见18.98元,余下均「潜水」。公司上月底公布,於稳定价格期,联席全球协调人并无行使超额配股权,相关配股权已失效。
海普瑞本周一公布,向子公司美国海普瑞增资不超6.9895亿元人民币。完成後,美国海普瑞的投资总额将增至不超过2.13亿美元,仍为公司全资子公司。另外,海普瑞上月中预计,上半年赚5.46-6.01亿人民币,按年最多增长10%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.